IRON is a vital micronutrient of life. It functions to transport oxygen (via hemoglobin) and produce energy (via electron transfer). Thus, its deficiency has far-reaching consequences. Iron Deficiency (ID) is a widely underserved, unmet medical problem affecting mostly 15 million women and children in the US alone, and about 1.3 billion people worldwide. In developing countries in ROW, the prevalence is higher than the typical 25-30%. For e.g., in India, and Africa, > 55% and >40% of young women are at risk of IDA, respectively. ID can also manifest due to underlying diseases: inflammatory bowel disease (IBD), chronic kidney disease (CKD), obesity, post-bariatric surgery, etc. Severe iron deficiency that impairs the body’s ability to produce hemoglobin and red blood cells results in IDA and is the most common presentation of ID. Sustained iron deficiency impairs oxygen transport in the blood resulting in increased cardiac load, causing palpitations, fatigue, breathlessness, dizziness, and negatively impacts metabolism, musculoskeletal, neurological and immune systems, thereby significantly disrupting daily life function. The first line of treatment is oral iron supplements that are typically associated with poor absorption (~ 5-15%) and tolerability with gastrointestinal (GI) adverse effects ranging from mild to severe, for e.g., stomach discomfort, nausea, bloating, constipation and diarrhea, oftentimes leading to patient non-compliance, and a consequent treatment failure. The alternative standard-of-care is intravenous (IV) iron infusion which is invasive, is associated with a risk of hypersensitivity reactions like anaphylactic shocks, thereby requiring a clinical setting, long wait times and a steep healthcare cost burden. Though IV iron has a greater bioavailability, the high payload of iron entering the systemic circulation at once may also cause moderate to severe side-effects ranging from joint/muscle pain, ‘iron’ flu, bloating, GI and skin issues, etc. Currently, there is no solution comprising the benefits of both orals and IV, without their respective downsides. Keylika seeks to bridge this gap with its proprietary transdermal iron. NistuFe combines the efficacy of IV iron with the convenience of oral iron, without the adverse effects of either, and will provide superior clinical outcomes at the convenience of a patient’s home.